To explore the effects of TRIP13 on drug resistance in MM, TRIP13-OE MM cell line ARP1 and OCI-My5 or empty vector-transfected cells were treated with different concentrations of anticancer reagents: proteasome inhibitor Bortezomib or topoisomerase inhibitor etoposide. The gene discussed is TRIP13; the disease is Miyoshi myopathy.